Related Experiment Video

Updated: Jul 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Current aspects of defibrillator therapy in congestive heart failure]

H J Trappe1, M Meine, P Pfitzner

  • 1Medizinische Klinik II (Schwerpunkte Kardiologie und Angiologie), Universitätsklinik Marienhospital, Ruhr-Universität Bochum, Hölkeskampring 40, 44625 Herne.

Zeitschrift Fur Kardiologie
|March 23, 2001
PubMed

Insights

Implantable cardioverter-defibrillator (ICD) therapy benefits patients with ventricular arrhythmias and impaired left ventricular (LV) function, though survival depends on LV dysfunction severity. Aggressive heart failure treatment alongside ICDs is crucial for better outcomes.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • The efficacy of implantable cardioverter-defibrillators (ICDs) in patients with life-threatening ventricular arrhythmias and impaired left ventricular (LV) function remains an area of ongoing research.
  • Left ventricular dysfunction is a critical factor influencing outcomes in patients with ventricular arrhythmias.

Purpose of the Study:

  • To evaluate the long-term effects and survival rates of implantable cardioverter-defibrillator (ICD) therapy in patients with varying degrees of left ventricular (LV) dysfunction.
  • To assess the impact of New York Heart Association (NYHA) functional class on mortality and ICD shock frequency.

Main Methods:

  • A follow-up study of 410 patients (mean age 57 years) who received ICD implants was conducted.
  • Left ventricular function was assessed using the New York Heart Association (NYHA) functional classification.
  • Data on perioperative mortality, causes of death, survival rates, and ICD shock incidence were collected and analyzed over a mean follow-up of 28 months.

Main Results:

  • Perioperative mortality was higher with epicardial ICD implantation (5%) compared to transvenous ( < 1%).
  • Overall 3-year survival rates ranged from 92% to 96% for arrhythmic mortality across NYHA classes I-III, with 84% survival at 5-7 years for NYHA class II-III.
  • 82% of patients received ICD shocks, with higher shock frequency observed in patients with more severe LV dysfunction (NYHA class III).

Conclusions:

  • Implantable cardioverter-defibrillator (ICD) therapy provides survival benefits for patients with left ventricular (LV) dysfunction and ventricular arrhythmias.
  • Patient survival is significantly influenced by the degree of left ventricular dysfunction.
  • Aggressive management of heart failure, in addition to ICD therapy, is essential for optimizing outcomes in this patient population.

More Related Videos

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine05:36

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...